Data calls the shots.
At PRA’s Center for Vaccine Research, we apply our hands-on, boutique operating model with the capabilities of a global CRO to solve your challenges and customize solutions to meet your unique needs. We use data intelligence to identify and target endemic areas and areas with high disease prevalence to improve study design, site selection, and enrollment forecasting in ways that others cannot. Our solutions are designed to deliver rapid and predictable outcomes, as well as cost-effective trials that prevent the spread of unnecessary disease.Read how we’re helping to shape the future of vaccine research and development.
Bringing personalized, passionate care to vaccine research.
Subjects Enrolled Globally216,000+
Global Vaccine Study Sites3,300+
PRA-Managed Vaccine Studies140+
Our small but specialized team of experts is powered by the infrastructure, technologies, and capabilities of a global CRO. We bring the same focused, passionate care and attention that you do to preventing diseases to every vaccine study we work on, while ensuring you have all the resources needed to push your research forward. We leverage our deep data to personalize study design and improve site selection, ensuring you meet rapid enrollment targets.See how we met stringent timelines in a recent Ebola vaccine trial.
Strategic partnerships that simplify the start-up and monitoring processes.
We’ve partnered with the Alliance for Multispecialty Research (AMR) to bring efficiency to every step of your vaccine development—from protocol to database lock, from sponsor to site. By following AMR’s Core Team Process, we can provide a single start-up and contracting process that covers 14 sites. Every clinical study is assigned a core team lead to act as a single point of contact. This simplifies and streamlines the start-up and monitoring processes, allowing us to meet or exceed enrollment expectations consistently.
Together, our vaccine partnership helps facilitate identification of appropriate populations for vaccine studies, reducing development times and bringing much-needed vaccines to market sooner.Learn more about our unique vaccine partnership with the Alliance for Multispecialty Research.
COVID-19 Prevents Children from Receiving Important Vaccinations
Measles is a highly contagious disease that often affects children, and may be fatal. Harris Dalrymple, PRA’s Executive Director of Scientific…
In this third week of January, we bring our readers research updates on antibiotic resistance, and how in comparison, resistance to vaccines is rare.…
Ask the Experts: What Does the World Need to Know About TB?
According to the World Health Organization, Tuberculosis (TB) is the world’s leading infectious cause of death. Despite significant advances in…